Holen Sie sich die Stockscreener-App
2.33
1.30%
0.03
Handel nachbörslich:
2.33
Schlusskurs vom Vortag:
$2.30
Offen:
$2.31
24-Stunden-Volumen:
302.40K
Relative Volume:
0.46
Marktkapitalisierung:
$166.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-104.08M
KGV:
-1.6561
EPS:
-1.4069
Netto-Cashflow:
$-89.91M
1W Leistung:
-3.32%
1M Leistung:
-12.08%
6M Leistung:
+18.27%
1J Leistung:
+5.91%
1-Tages-Spanne:
$2.2406
$2.34
1-Wochen-Bereich:
$2.2406
$2.48
52-Wochen-Spanne:
$1.70
$3.72
Nkarta Inc Stock (NKTX) Company Profile
Firmenname
Nkarta Inc
Sektor
Branche
Telefon
(925) 407-1049
Adresse
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.33 | 171.18M | 0 | -104.08M | -89.91M | -1.4069 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-09 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-08-14 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-22 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-28 | Eingeleitet | Needham | Buy |
| 2022-07-18 | Eingeleitet | SVB Leerink | Outperform |
| 2022-03-11 | Eingeleitet | Raymond James | Outperform |
| 2022-03-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-06 | Eingeleitet | William Blair | Outperform |
| 2021-11-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2020-08-04 | Eingeleitet | Cowen | Outperform |
| 2020-08-04 | Eingeleitet | Evercore ISI | Outperform |
| 2020-08-04 | Eingeleitet | Mizuho | Buy |
| 2020-08-04 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nkarta Inc Aktie (NKTX) Neueste Nachrichten
Nkarta (NASDAQ:NKTX) Stock Rating Lowered by Wall Street Zen - marketbeat.com
Stifel cuts Nkarta stock price target on updated model By Investing.com - Investing.com Canada
Stifel cuts Nkarta stock price target on updated model - Investing.com
Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price - marketbeat.com
Nkarta Inc (NASDAQ: NKTX) Stock Price, News & Analysis - kalkine.ca
Equities Analysts Set Expectations for Nkarta Q3 Earnings - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT) - The Globe and Mail
NKARTA STOCK : BIG PRICE RECOVERY | NKTX STOCK Rinku Singh (KkQAHM32gq) - Mshale
Nkarta, Inc. Stock 12‑Month Price Target Cut to $11, Implies 347% Upside - TradingView
H.C. Wainwright cuts Nkarta stock price target on trial progress - Investing.com
NKARTA, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $14 FROM $16 - Bitget
Nkarta, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Nkarta (NASDAQ:NKTX) Posts Quarterly Earnings Results, Misses Estimates By $0.18 EPS - marketbeat.com
Nkarta Q2 EPS of $(0.54) misses $(0.38) analyst estimate - scanx.trade
Nkarta Reports Continued Enrollment in Ntrust Autoimmune Trials and $243.2 Million Cash Position, Reaffirms Runway Into 2029 - Quiver Quantitative
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights - GlobeNewswire
Nkarta, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Nkarta Inc (NKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts - marketbeat.com
Nkarta, Inc. expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Nkarta (NKTX) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Nkarta Inc. (NKTX) Drops 2.79% to $2.09 as Key Support Level Comes into FocusLate Stage Breakouts - dars.gov.et
Nkarta (NASDAQ:NKTX) Upgraded at Wall Street Zen - MarketBeat
Nkarta Stock Price Forecast. Should You Buy NKTX? - StockInvest.us
Nkarta, Inc. Revenue Breakdown – NASDAQ:NKTX - TradingView
NKTX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Nkarta Inc (NKTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NKTX|Nkarta Inc|Price:2.245|Chg%:-0.025 - TradingKey
Nkarta Inc (NKTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nkarta Inc. (NKTX) Edges Higher: Biotech Stock Tests Key Levels After 3.5% GainEarly Entry Signals - dars.gov.et
Nkarta Market Sentiment - Benzinga España
Nkarta Inc (NKTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nkarta Inc (NKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nkarta Inc (NKTX) Balance Sheet - TradingKey
Nkarta Inc (NKTX) Cash Flow - TradingKey
Nkarta Inc (NKTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nkarta Inc. (NKTX) Holds Steady at $2.6 as Consolidation ContinuesPassive Flow - dars.gov.et
Nkarta Inc. (NKTX) Declines 4.9% as Biotech Headwinds Persist — Key Support in FocusTICK Divergence - dars.gov.et
Nkarta Inc. (NKTX) Slides 5% as Biotech Momentum Fades, Tests Near-Term SupportHigh Reward Trades - dars.gov.et
NKTX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Double-Digit Stock GainProfit Growth Outlook - dars.gov.et
Nkarta (NKTX) Stock Analysis Report | Financials & Insights - Benzinga España
NKTX Q1 2026 Earnings: Narrower-Than-Expected Loss in Early-Stage BiotechEarnings Revision Downgrade - dars.gov.et
Nkarta Inc (NKTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nkarta at H.C. Wainwright cell therapy conference: autoimmune push By Investing.com - Investing.com India
Enterprise value to EBITDA forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Sahm
Price to sales forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
Price to book forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
Enterprise value to revenue forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
Price to earnings forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
Finanzdaten der Nkarta Inc-Aktie (NKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):